In a different approach, targeting ADAM9 with the novel antibody–drug conjugate IMGC936 has shown preclinical efficacy by causing cytotoxicity in ADAM9-positive tumour cell lines and potent antitumor activity in xenograft models [131]. The gene discussed is ADAM9; the disease is neoplasm.